BioMarin: A Rare Disease Specialist With An Eye On The Long-Term
This article was originally published in The Pink Sheet Daily
Executive Summary
BioMarin is in the midst of a pivotal year, with several near-term data catalysts, the most important of which will be Phase III data on GALNS for the rare disease MPS IV.
You may also be interested in...
BioMarin Takes One Step Closer To Profitability With Positive GALNS Data
The orphan drug company reported positive Phase III data on its candidate for patients with the rare disease MPS IV and expects to file GALNS for FDA approval in the first quarter.
BioMarin Takes One Step Closer To Profitability With Positive GALNS Data
The orphan drug company reported positive Phase III data on its candidate for patients with the rare disease MPS IV and expects to file GALNS for FDA approval in the first quarter.
BioMarin May Be On Cusp Of Profitability, With GALNS The Key Determining Factor
At the Canaccord Genuity Global Growth Conference, the rare disease-focused biotech reiterated its goal to reach profitability in the near future with five pipeline programs potentially augmenting a portfolio of four marketed products.